New vaginal film uses antibodies to block sperm – first human trial underway

NCT ID NCT07222020

Recruiting now Prevention Sponsor: ZabBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether a vaginal film containing an anti-sperm antibody (KB15A) is safe for healthy women. Twenty-four participants will receive either the active film or a placebo, first as single doses and then daily for 14 days. Researchers will monitor for side effects and measure how much antibody stays in the vagina and enters the bloodstream. The goal is to see if this approach could one day become a new, hormone-free contraceptive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KB15A monoclonal antibody vaginal film
What this could lead to: If successful, this could lead to a new, non-hormonal contraceptive option that women can use on demand.
What could go wrong: This is a very early Phase 1 safety trial with only 24 participants. It is not designed to test whether the film actually prevents pregnancy, and many early-stage ideas never advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS

Contacts and locations

Locations

Virginia Health Sciences at Old Dominion University
RECRUITING

Norfolk, Virginia, 23507, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.